Compare Amphastar Pharmaceuticals Inc (AMPH) vs Intel Corp (INTC) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Intel (INTC) trades at $109.84, down 2.4% on the day, with a bearish technical signal but recent earnings beats. The stock shows mixed fundamentals with a high P/E of 904.17 and negative net margin of -5.9%, though operating cash flow improved to $9.70B in 2025. News highlights government support and turnaround progress, with consensus price target at $99.70.

Outlook remains cautious due to profitability challenges and competitive pressures, but long-term growth potential exists from AI and foundry expansions. Key risks include execution on capital investments and market share loss to AMD. Analyst sentiment is mixed with 36.9% buy ratings, suggesting patience for turnaround results.